Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial

OHMACHI Ken; TOBINAI Kensei; KINOSHITA Tomohiro; ISHIKAWA Takayuki; HATAKE Kiyohiko; ICHIKAWA Satoshi; OHMINE Ken; KAMITSUJI Yuri; CHOI Ilseung; CHOU Takaaki; TSUKASAKI Kunihiro; KUMAGAI Kyoya; TANIWAKI Masafumi; UCHIDA Toshiki; KIKUKAWA Yoshitaka; KUBO Kohmei; MIHARA Keichiro; TSUKAMOTO Norifumi; IZUTSU Koji; YOSHIDA Isao; ISHIDA Fumihiro; USUI Noriko; IIDA Shinsuke; MURAYAMA Tohru; UEDA Eisuke; KURIKI Hiroshi; ANDO Kiyoshi

Art

J-GLOBAL ID：201802265890481388 Reference number：18A2175515

Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial

過去に治療を受けていない濾胞性リンパ腫患者でのオビヌツズマブの有効性と安全性:日本でのランダム化第III相GALLIUM試験に参加した患者のサブグループ解析

Publisher site {{ this.onShowPLink() }} Copy service {{ this.onShowCLink("http://jdream3.com/copy/?sid=JGLOBAL&noSystem=1&documentNoArray=18A2175515&COPY=1") }}
Access JDreamⅢ for advanced search and analysis. {{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A2175515&from=J-GLOBAL&jstjournalNo=F0888A") }}

Author (27)： , , , , , , , , , , , , , , , , , , , , , , , , , ,
Material：
Volume： 108 Issue： 5 Page： 499-509 Publication year： Nov. 2018
JST Material Number： F0888A ISSN： 0925-5710 CODEN： IJHEEY Document type： Article
Article type：原著論文 Country of issue： Germany, Federal Republic of (DEU) Language： ENGLISH (EN)

,...
,...

To see more with JDream III (charged). {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A2175515&from=J-GLOBAL&jstjournalNo=F0888A") }}

Clinical application of antitumor(=antineoplastic)drugs , Blood cell tumors(=neoplasms) , Drug therapy(=pharmacotherapy)for tumors

Reference (30)：

Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725-32.
Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-23.
Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25:1986-92.
Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi JF, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008;112:4824-31.
Rituxan injection prescribing information. 2017. http://www.info.pmda.go.jp/downfiles/ph/PDF/380101_4291407A1027_2_23.pdf. Accessed June 2018.

ｍore...

, , , , , , , , , , ,

Return to Previous Page